美国Invitrogen CellzDirect    
全球生命技术行业的领导者Invitrogen(英杰生命技术有限公司)新近成功收购了CellzDirect Inc (CellzDirect公司)。这是继去年成功收购Cascade Biologics之后，Invitrogen在细胞生物学领域的又一个重大举措。

CellzDirect是一家私有的生物技术公司，成立于2001年，总部位于美国北卡罗林那州的德罕市(Durham, North Carolina, USA)，向生物公司和制药公司提供高品质的细胞产品和服务，主要关注的领域包括药物代谢，药物交互作用和药物转运体等。在CellzDirect的支持下，科学家们可以更好的开展科研工作，加速安全、高效药品的研发。

Hepatocyte(人肝细胞)是CellzDirect的主要产品之一，它是新药检测的重要工具。原代hepatocyte能够预测各组分在肝中对酶代谢的影响，是现今该领域最受关注的工具，也是FDA要求使用的检测方法，它可以大大降低临床试验失败造成的巨大损失。因此，CellzDirect的产品主要用于生物和制药公司的研发。原代hepatocyte也可用于生物医疗，用来研究肝的疾病，和细胞功能的下游价值，因为体内的每一个系统都与肝密切相关。

CellzDirect自成立以来，以其独特而又健康的组织来源网络，高品质hepatocyte的制备，雄厚的检测平台，和出色的结果分析，取得了飞速的发展，平均每年以70%的速度上升。由于CellzDirect在科学界的领导地位，与科学和工业领域权威的磋商，和持续不断的与医疗团体、制定规章的机构和其用户的沟通，使其在原代细胞的供应者中一枝独秀。

CellzDirect的加盟，无疑会大大推进Invitrogen在生命技术行业，特别是在细胞生物学领域的领导地位。对于原旗下的GIBCO®品牌——这一全球细胞培养领域的泰斗，CellzDirect是其非常有益的补充和促进。CellzDirect高价值的产品和服务，进一步将Invitrogen细胞系统的产品线完善和升值，至此，Invitrogen已拥有了完整的、高品质的细胞系统的产品线，包括原代细胞，培养基，三维基质，生长因子，等等。
 CellzDirect is building a preeminent cell-based bioscience company that provides innovative ADME products and services to expedite the development of safe, effective drugs.

Our Company

Now part of the Invitrogen family, CellzDirect provides high-quality in vitro ADME cell products and contract laboratory and consulting services focused primarily on drug metabolism and transport. Our clients include leaders in the pharmaceutical, biotech, academic, chemical and consumer products fields as well as government agencies. With CellzDirect’s support, scientists conduct research that accelerates the discovery of safe and effective drugs.

CellzDirect offers a complete line of fresh and cryopreserved hepatocytes and liver subcellular fractions, and transporters derived from a variety of species, including human, non-human primate, dog, rat and mouse. Members of our scientific staff have dedicated up to 20 years on research to optimize the isolation conditions and culture techniques by species.

Our service offerings include drug-drug interaction studies, drug metabolism studies and hepatotoxicity studies, such as enzyme induction and inhibition, reaction phenotyping, metabolite stability and profiling, and P-gp assays. These studies can be conducted in GLP (Good Laboratory Practices) or non-GLP formats, and study data can be presented for FDA submissions.